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Objective: To quantify modiﬁcation of functional capacity in a three-year period in a group
of  patients with rheumatoid arthritis (RA) using HAQ and EPM-ROM inventories.
Methods: Forty patients with RA on methotrexate (MTX) as disease-modifying antirheumatic
drug (DMARD) were followed for up to three years. The functional status was  assessed at
the  beginning and end of the period by HAQ and EPM-ROM.
Results: Thirty-two patients were retrieved, with initial HAQ score of 1.14 ± 0.49 (mean ± SD)
and EPM-ROM score of 5.8 ± 2.75. After an average period of three years, the HAQ score was
1.13  ± 0.49 and EPM-ROM score, 6.81 ± 3.66. In the subgroup of seven patients submitted to
orthopedic surgery, HAQ score decreased from 0.84 ± 0.72 to 1.64 ± 0.56 and the EPM-ROM
score, from 5.8 ± 1.80 to 8.3 ± 0.74. In the subgroup of non-operated patients, HAQ score
varied from 1.2 ± 0.45 to 1.07 ± 0.70 and EPM-ROM score, from 5.7 ± 3.06 to 6.4 ± 3.90.
Conclusion: In a group of RA patients in use of only MTX as DMARD, there was little change on
HAQ  score and EPM-ROM scores over the average period of three years. Worsening functional
capacity was observed in the group of operated patients in comparison to the not operated
ones. This fact alerts us to the need for use of broader therapeutic regimens availability of
musculoskeletal surgeries in a timely manner in patients with RA.
©  2014 Elsevier Editora Ltda. All rights reserved.
Acompanhamento  da  capacidade  funcional  de  pacientes  com  artrite
reumatoide  por  três  anos
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Objetivo: Quantiﬁcar a modiﬁcac¸ão da capacidade funcional em um período de três anos
Artrite reumatoide
Capacidade funcional
HAQ
EPM-ROM
em  um grupo de pacientes com artrite reumatoide (AR), utilizando os inventários HAQ e
EPM-ROM.
Métodos: Quarenta pacientes com AR em tratamento com metotrexato (MTX) como fármaco
antirreumático modiﬁcador da doenc¸a (DMARD) foram acompanhados por até três anos. O
estado funcional foi avaliado no início e no ﬁnal do período por HAQ e EPM-ROM.
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Resultados: Trinta e dois pacientes foram recuperados, com escore HAQ inicial de 1,14 ± 0,49
(média ± DP) e EPM-ROM de 5,8 ± 2,75. Após um período médio de três anos, o HAQ foi de
1,13 ± 0,49 e EPM-ROM em 6,81 ± 3,66. No subgrupo de sete pacientes submetidos a cirur-
gia  ortopédica, o HAQ diminuiu de 0,84 ± 0,72 para 1,64 ± 0,56; e o EPM-ROM, de 5,8 ± 1,80
para 8,3 ± 0,74. No subgrupo de pacientes não operados, o HAQ variou de 1,2 ± 0,45 para
1,07  ± 0,70; e o EPM-ROM, de 5,7 ± 3,06 para 6,4 ± 3,90.
Conclusão: Em um grupo de pacientes com AR medicados apenas com MTX como DMARD,
houve pouca mudanc¸a nas pontuac¸ões HAQ e EPM-ROM durante o período médio de três
anos.  Observou-se agravamento da capacidade funcional no grupo de pacientes operados,
em  comparac¸ão com os não operados. Este fato nos alerta para a necessidade do uso de
esquemas terapêuticos mais abrangentes e de maior disponibilidade de cirurgias muscu-
loesqueléticas, em tempo hábil, em pacientes com AR.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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musculoskeletal or neurological disorders, fractures with jointntroduction
heumatoid arthritis (RA) is a chronic inﬂammatory disease
n which the joint inﬂammation presents as synovitis. The
nﬂammation causes joint pain, swelling, and stiffness, as
ell as systemic symptoms such as fatigue, weight loss and
nemia. The synovitis is the main factor that leads to joint
estruction and, if untreated, may progress to serious joint
amage, with loss of functional capacity.1
RA is a condition that affects approximately 0.5–1% of the
dult population worldwide, and its occurrence is observed in
ll ethnic groups. There is a predominance of females (two to
hree times, compared to males), occurring mainly in patients
etween the fourth and sixth decades of life, although there
re occurrences of RA in all age groups.2
The negative consequences for physical functioning in RA
atients are multidimensional, with loss of muscle strength
nd endurance, besides the loss of range of motion (ROM)
f joints, due to changes caused by the disease. For a proper
nderstanding of the situation of the patient, a multifaceted
iew is required, because the only use of laboratory tests will
ot allow a comprehensive assessment of his/her functional
apacity.3
Functional capacity is a key factor of morbidity and a pre-
ictor of mortality4 in RA patients. The Health Assessment
uestionnaire (HAQ) is a commonly used tool to assess the
unctional status in RA patients, but some studies have shown
n inverse relationship between sensitivity to change in HAQ
nd disease duration, so that the duration of the disease inﬂu-
nces the degree of functional improvement.5
HAQ was developed by Fries et al. (1980)6 to assess func-
ional capacity in RA; and the dysfunction occurs early in the
isease, due to factors that are not entirely clear.
The pain per se can lead to functional loss, even in the
bsence of radiological changes, which only become evident
ith the persistence of synovitis.7 HAQ has been translated
nd validated into many  languages, including Brazilian Por-
uguese by Ferraz et al. in 1990.8
Functional capacity in RA can also be assessed by EPM-
OM, which is a standardized measure of the potential range
f motion of joints in upper and lower limbs.9 The scale
ssesses ROM of 10 large-and-small, right-and-left joints by
sing a goniometer.10The progression of joint dysfunction occurs in a subclinical,
slow and progressive way in the different stages of the disease,
which complicates the acceptance of surgical indication by
RA patients. However, the indication of surgery must be done
early, in order to avoid the onset of joint deformities.11
In our environment, there are no studies on the long-term
outcome of functional capacity in RA patients who were not
treated with biologicals. This study portrays the situation of
availability of musculoskeletal surgeries performed in a timely
fashion in patients seen in the Public Health Service.
“In our country there are no studies on the long-term out-
come of functional capacity of patients with RA taking
biologic medication. This study portrays the situation of
availability of musculoskeletal surgeries in a timely fashion
in patients seen in the Public Health Service. Consider-
ing that HAQ and EPM-ROM may reﬂect the changes in
functional capacity over time,12 this study assessed the
modiﬁcation of the indices in question as a result param-
eter of indication of orthopedic surgery within a 3-year
period in RA patients.”
Objectives
This study aims to quantify the change in the functional
capacity of RA patients treated routinely at our Service of
Rheumatology, Universidade Federal de São Paulo.
Methods
This prospective study involved 40 RA patients according to
American College of Rheumatology criteria,13 all aged over 18
years at disease onset. All patients were informed on the con-
tent of the research and agreed to participate in the study
by signing a consent form. RA patients in functional classes
2 and 314 treated with corticosteroids, nonsteroidal anti-
inﬂammatory drugs, and methotrexate as disease-modifying
antirheumatic drug (DMARD) were included in this study.
Patients who used other DMARDs, or those with some pathol-
ogy that would interfere with their movement, e.g., otherdeformity, or with congenital malformation were excluded.
Patients with diabetes mellitus and alcohol or illegal drug
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Table 1 – Clinical and demographic characteristics.
Gender (women/men) 29:3
Average age (years) 53.8 (13)
Min/Max 28–75 years
Race, n (%)
White 15 (46.9)
Mixed race (“pardos”) 12 (37.5)
Black 3 (9.4)
Oriental 2 (6.3)
Duration of illness 12.2  (7.4)
Min/Max 4–33 years
Number of inﬂamed joints 5 (7.1)
HAQ, baseline 1.14 (0.49)
HAQ, ﬁnal 1.13 (0.49)
EPM-ROM (DP), baseline 5.8 (2.75)
EPM-ROM (DP), ﬁnal 6.81 (3.66)
Methotrexate (%) 23 (73.6)
Continuous data expressed as mean (SD), minimum and maximum
impairment according to HAQ and EPM-ROM scores. After
a mean follow-up of three years, the frequency of patients
who had greater than 20% loss of functional capacity was
Table 2 – Characteristics of RA patients who  underwent
surgery during the study period.
Conservative
treatment
Surgery
Gender (women/men) 22:3 7:0
Age (years) 50.0 49.7
Min/Max 28–75 31–69
Disease duration (years) 11.3 14.2
Min/Max 4–33 8–23
Morning stiffness (minutes) 29.2 23.5
Min/Max 0–360 0–120
Number of inﬂamed joints 5.2  764  r e v b r a s r e u m a
users were also excluded. Our patients were selected sequen-
tially, being inquired about duration of the disease, presence
of morning stiffness (in minutes) and medications used at the
time of enrollment. The overall clinical assessment and the
counting of inﬂamed joints were performed by a rheumatol-
ogist, and HAQ and EPM-ROM tools were applied by one of
the authors of this study (Oliveira LM). After an average 3-year
period, 32 of those patients still being monitored at the out-
patient service of Rheumatology, Universidade Federal de São
Paulo, were reassessed.
Considering the occurrence of a 10% loss of functional
capacity even in healthy individuals after the age of 50,15 we
set the rate of loss of functional capacity expected by HAQ in
RA in 20%. Thus, we  compared baseline and ﬁnal assessment
data with respect to the loss of function, using HAQ (greater or
lesser than 20%) and with respect to whether or not perform
a surgery.
Continuous data were presented as mean (standard devi-
ation – SD) and minimum and maximum values. Categorical
data were expressed as absolute number and percentage. For
the comparison between baseline and ﬁnal assessments of
variables (e.g., medications in use and function loss greater or
lesser than 20% measured by HAQ), the chi-square or Fisher’s
exact test was used.
Comparisons between continuous variables, such as HAQ
and EPM-ROM scores and HAQ and EPM-ROM score changes,
were only descriptive, due to the limitation imposed by the
sample size. The correlation between variables was performed
using the Spearman test.
The statistical package SPSS, version 15.0, was used, and
signiﬁcance was set at 5%.
Results
After a 3-year period, of those 40 patients included in the study
we could reassess 32 subjects. Thus, eight patients were not
reassessed: three had died and ﬁve failed to visit the service
of Rheumatology. The characteristics of the group are shown
in Table 1.
Seven patients underwent orthopedic surgery during the
time period of this study and their data are described in
Table 2. Table 3 shows the values for HAQ and EPM-ROM for
patients submitted or not to surgery. Of the seven patients
surgically treated, four underwent more  than one procedure.
The operations performed in the upper limbs (n = 5) were: syn-
ovectomy in three patients, wrist ﬁxation in one patient, and
metacarpophalangeal prosthesis application in one patient.
The surgeries performed in the lower limbs (n = 9) were: syn-
ovectomy in the foot of a patient, a talocalcaneal ﬁxation on
another and knee prosthesis application in three patients.
Table 4 shows the comparison of patients stratiﬁed with
respect to loss of function by HAQ and whether or not a surgery
was performed.
With respect to surgery procedures, although the frequency
of patients who  had greater than 20% loss of functional capac-
ity was not signiﬁcant (Fisher, P = 0.16), those patients who
underwent surgery had a three times greater risk of suffer-
ing loss of functional capacity greater than 20% during thevalues.
Categorical data in absolute numbers, n (percentage).
study period (hazard ratio = 3.42) compared with patients not
operated.
A correlation was noted between number of inﬂamed joints
and baseline EPM-ROM score (0.46); between baseline EPM-
ROM and baseline HAQ (0.46); between ﬁnal EPM-ROM score
and disease duration (0.45); and between disease duration
and EPM-ROM change (difference between baseline and ﬁnal
scores). A strong correlation was noted between ﬁnal HAQ
score and HAQ change (0.74), inﬂuenced by the subgroup of
patients who underwent surgery (Table 5).
Discussion
This prospective study involved 32 RA patients aged over
18 years at disease onset and with moderate functionalMin/Max 0–26 0–30
Average, minimum and maximum values.
Categorical data in absolute numbers, n.
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Table 3 – HAQ and EPM-ROM scores for patients who were  or not submitted to orthopedic surgery.
Baseline Final Methotrexate use
Surgery HAQ 0.84 (0.72) HAQ 1.64 (0.56) 4 (57%)
n = 7 EPM-ROM 5.8 (1.80) EPM-ROM 8.3 (0.74)
Without surgery HAQ 1.20 (0.45) HAQ 1.07 (0.70) 21 (84%)
n = 25 EPM-ROM 5.7 (3.06) EPM-ROM 6.4 (3.90)
Data expressed as mean (SD).
Table 4 – Loss of function as measured by HAQ after
three years of progression.
Loss of function >20% <20%
Surgery 4 (57%) 3 (43%)
Without surgery 7 (28%) 18 (72%)
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ot signiﬁcant. Patients who underwent surgery had a three
imes greater risk of functional capacity loss greater than 20%
uring the study period compared with not surgically treated
atients.
Our data indicate a relative score stability, not only for
AQ,16 but also for EPM-ROM over time. Although extensively
sed, the exclusive use of HAQ has proven more  suitable to
valuate RA activity,17 while EPM-ROM is a more  sensitive tool
o changes in functional capacity.10 The use of EPM-ROM in
his study has provided objective data about the ROM needed
o performing activities of daily living. In fact, the EPM-ROM
core is sensitive to the modiﬁcation of functional status,
ranslating the goniometry required to perform the basic activ-
ties of life.17
Even in healthy individuals, there is loss of functional
apacity throughout life;18 and in RA patients, such a loss is
ore signiﬁcant.19 In our sample of RA patients with a mean
ge of 58 years, an HAQ score of 1.1 is equivalent to the score
or people aged 85 years.18 Sokka et al., assessing functional
apacity in RA patients, established that HAQ values smaller
han 1 would mean a milder disease, while values above 2
ould suggest a severe illness.12 The annual increase in HAQ
core found by these authors was conﬁrmed by Scott et al.
hese authors found an annual increase of 1% in HAQ score.20
lthough the literature considers a 0.24-change in HAQ as clin-
cally relevant,21 reductions of 0.19 can already considered as
inimal improvement in function.20
The functional capacity measured by HAQ is inﬂuenced not
nly by age or duration of disease, but also by levels of pain
Table 5 – Correlations found among clinical data.
Baseline EPM-ROM scoring Final EP
Inﬂamed joints (n) 0.46 N
Duration of disease NS 0
HAQ, baseline 0.46 N
Final HAQ scoring NS N
EPM-ROM, baseline NS 0
Spearman correlation, NS, not signiﬁcant.and medications used. In Brazilian patients, there was a faster
progression in HAQ scores compared to Spanish patients. This
ﬁnding was attributed to the difference in the pain assessment
and medications used.21 At that time, there was scarce access
to biologic drugs in several centers in Brazil, while in Spain
these medications were already widely available.
HAQ can predict the severity and dysfunction caused by
RA during the progression of the disease – which is not evi-
dent with the use of other clinical measures. The functional
loss after ﬁve years is related to female gender, older age at
disease onset, HAQ >1 in the ﬁrst assessment, comorbidities
and depression.16 In addition to a positive correlation with dis-
ease duration, HAQ presents also a negative correlation with
socioeconomic status.20
In the present study, we observed a slight improvement
in functional capacity measured by HAQ in the group of
patients who did not undergo surgery and a signiﬁcant wors-
ening in the operated group. One can interpret this ﬁnding
as a difference in disease severity between groups. Allegedly,
the group not operated would suffer a less aggressive dis-
ease, although with a disease duration similar to that of the
operated group. Thus, the more  favorable progression of the
non-operated group may reﬂect a condition more  suscepti-
ble to control by medication. A worsening of both HAQ and
EPM-ROM scores was observed in the RA group who  under-
went orthopedic surgery, denoting that their surgery may
have occurred late, when the anatomical deformities (e.g.,
musculoskeletal impairment) already installed would prevent
functional improvement of the joint.
Back when the patients in this study showed the ﬁrst symp-
toms of RA, biologicals were not available in the Public Health
Service. Currently the importance of the early use of DMARDs
and biologicals in controlling the course of the disease in
its ﬁrst years has already been established. This window of
opportunity may have been lost by the patients in this study,
who had only methotrexate available as DMARD. Our ﬁndings
agree with Sokka et al.’s, which emphasize the positive impact
of an early use of DMARDs in functional capacity measured
M-ROM scoring EPM-ROM change HAQ change
S NS NS
.45 0.48 NS
S NS NS
S NS 0.74
.53 NS NS
 t o l .66  r e v b r a s r e u m a
by HAQ. We  can add to this the ﬁnding that functional dis-
ability was a predictor factor of mortality in RA.12 Pain and
joint mobility are considered as important factors limiting
the functional capacity of RA patients.3,22,23 The loss of func-
tional capacity occurs early in the disease, with the presence of
acute inﬂammation.24 With the early use of DMARDs and after
controlling the disease activity, a functional recovery occurs,
followed by structural lesions that settle slowly and cumu-
latively. Thus, the functional deterioration may occur even
before the radiographic changes, which become relevant after
a lapse of ﬁve years from the onset of the disease.7,20
An inverse correlation between HAQ score and ROM of
some joints, e.g. wrists, shoulders and knees, was observed.24
EPM-ROM takes into account the ROM ranges needed to
perform wide-ranging functions, and not just a percentage
of amplitude loss caused by the disease, which can differ
depending on the joint.8 Our data show the expected corre-
lation between the baseline evaluation by EPM-ROM and the
number of inﬂamed joints. We  also noted an EPM-ROM varia-
tion with the duration of disease, showing worsening in joint
mobilization capacity after a 3-year period.
In subjects with joint impairment consolidated by a disease
duration longer than 12 years, EPM-ROM remains stable, while
HAQ varies depending on the degree of disease activity.22
These questionnaires are complementary, to the extent that
HAQ is inﬂuenced by the subject’s adaptation to dysfunction
over time, while EPM-ROM reﬂects the capacity of the move-
ment itself.
Although the dysfunction due to pain and inﬂammation
can be modiﬁed by clinical and rehabilitative approaches, this
strategy may not be sufﬁcient in the context of the sum of
structural joint injuries, regardless of the surgical approach.25
The best time for surgery indication in RA remains to be
deﬁned, being hampered by the availability of surgical ser-
vices and the patient’s motivation.7,11,25 We  must add to this
the fact that, even when indicated early, the surgery acts in
an indirect manner in function improvement, i.e., through
improvement of pain, rather than through regaining func-
tional capacity.19 Few studies have evaluated the long-term
effect of surgical interventions. Benoni et al. demonstrated
improvement in pain in RA patients who underwent surgery
of lower limb joints after one year of follow-up. The improve-
ment in HAQ score of at least 0.2 occurred only in cases of
knee and hip surgery, but not in ankle and feet surgery.26 On
the other hand, March et al. observed a reduction in HAQ only
in patients undergoing knee arthroplasty, and stability in HAQ
in those undergoing hip arthroplasty.19 Therefore, total HAQ
does not reﬂect the potentially expected functional improve-
ment after an orthopedic surgery in RA patients; and clinical
practice shows that the modiﬁcation of HAQ has value as
a measure of the effect of other therapeutic modalities in
RA.27
In our study, we observed a positive correlation between
the ﬁnal score of the HAQ and its changes over the 3-year
period, inﬂuenced by the subgroup of patients undergoing
surgery. This ﬁnding highlights the deterioration of functional
capacity in the group of operated patients, which is in agree-
ment with other authors that the effect of arthroplasty in
RA is more  prominent in relieving pain than in the recovery
of function.19,26,27 Considering that disease activity is a key 2 0 1 5;5 5(1):62–67
determinant factor to explain the loss of functional capac-
ity, patients treated by rheumatologists have a more  favorable
progression of AR versus those treated by physicians from
other specialties.12
Furthermore, we observed lower baseline HAQ scores in
the surgery group compared to the conservatively treated
group. No statistical analysis could be performed between the
two groups, in view of the diversity in the group of patients
operated and the small sample size. In four patients, more
than one type of surgery was performed, and three patients
underwent surgery both in their upper and lower limb. Two
patients underwent ankle surgery which, according to Benoni
et al., evolves unfavorably, with reduction of HAQ.27 As for
metacarpophalangeal arthroplasty, it is known that, although
the patient demonstrates satisfaction with improved pinch
and grip strength, the functional capacity shows modest
gains.28
Some of the limitations of this study reﬂect the deﬁcien-
cies in tertiary care of Public Health Services in our midst.
Among them, we can mention the difﬁculty in establishing
the diagnosis of RA within the window of opportunity that
would allow the preservation of joint function, as well as to
getting the surgery needed in a timely manner. In our country,
there are long waiting lines for treatment in the Public Health
Service, and this can contribute to the deterioration of func-
tional capacity to the point that, when ﬁnally the surgery is
performed, the preservation of function is no longer possible.
In this context, the heterogeneity with respect to disease dura-
tion and the small number of patients undergoing surgery are
included.
This study was limited to a baseline evaluation and to
another, after approximately three years of progression. The
fulﬁllment of interim evaluations, and in particular a pre-
operative assessment for the surgical group, could shed light
on the worst course of operated patients. These patients may
present a more  aggressive disease, and perhaps their func-
tional capacity was very poor at the time of surgery, justifying
their unfavorable outcome.
Finally, patients taking biologic medications were not
included in this study. It is not yet clear whether the biolog-
icals are responsible for a reduction in surgical indications
in RA patients.24,25,29 In general, it is known that the early
use of DMARDs in RA tends to decrease the disease pro-
gression, improve quality of life and also reduce the costs of
hospitalization, surgical procedures, and the long periods of
rehabilitation.11,30
Our data demonstrate that HAQ and EPM-ROM scores in a
group of RA patients seen in the Public Health Service have
not changed over an average 3-year period. The group of
patients undergoing orthopedic surgery experienced worsen-
ing of functional capacity versus the group of patients who
were not operated. This fact serves as a warning of the need to
use broader therapeutic regimens and also of the need for the
availability of musculoskeletal surgeries in a timely manner
for RA patients.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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